New study to reveal how well mpox vaccine works in HIV patients
NCT ID NCT05654883
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the mpox vaccine works and how safe it is in people with HIV compared to those without HIV. About 174 adults who either recently got the mpox vaccine or had a recent mpox infection will take part. The goal is to fill important knowledge gaps and help improve public health guidance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Can a smallpox vaccine stop mpox in its tracks?
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia